A comprehensive cancer center designated by the National Cancer Institute

Menu

Big Ten CRC study to help determine maximum dosage of ruxolitinib when combined with nivolumab in Hodgkin lymphoma patients

March 8, 2019
Big Ten CRC study to help determine maximum dosage of ruxolitinib when combined with nivolumab in Hodgkin lymphoma patients

March 8, 2019:

A phase I Big Ten Cancer Research Consortium study for adult patients with relapsed or refractory Classical Hodgkin lymphoma is open for accrual at Masonic Cancer Center, University of Minnesota; the University of Illinois Cancer Center; the University of Wisconsin Carbone Cancer Center; and the University of Iowa Holden Comprehensive Cancer Center. The study, BTCRC-HEM15-027, will help determine the safety (maximum tolerated dose) and efficacy of ruxolitinib, which blocks the main pathway dysregulated in Hodgkin lymphoma, when combined with the immunotherapy drug nivolumab.

Hodgkin lymphoma is a blood cancer involving the lymphoreticular system which presents with swollen lymph nodes, mediastinal mass, or organ infiltration by cancer cells.

Patients with Hodgkin lymphoma are often treated with chemotherapy drugs, radiation therapy, stem cell transplantation, or a combination of these treatments. Currently, brentuximab vedotin or nivolumab are approved treatments for Hodgkin lymphoma, and researchers are exploring alternatives that could work more effectively.

“Recent molecular insight in how Hodgkin lymphoma develops has led to the recognition that two unique genes are abnormally regulated with Hodgkin lymphoma,” said Veronika Bachanova, MD, PhD (pictured), sponsor-investigator of this study and a hematologist-oncologist at Masonic Cancer Center, University of Minnesota.

See the full story: